|Assessment Status||Rapid Review complete|
|Indication||Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.|
|Rapid review commissioned||09/08/2022|
|Rapid review completed||23/09/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that Buvidal® not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.